Terminated PHASE2 INTERVENTIONAL 1-arm NCT04365660

18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma

A Phase 2 Study of 18F FTC 146 PET/CT in Patients With Newly Diagnosed Osteosarcoma

Sponsor: Davidzon, Guido, M.D.

Updated 8 times since 2020 Last updated: Oct 26, 2023 Started: Jan 28, 2021 Primary completion: May 28, 2021 Completion: Jul 22, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

lack of accrual with no intent of continuing

Other Osteosarcoma trials with similar outcome

Browse all Osteosarcoma trials

This PHASE2 trial investigates Osteosarcoma and is currently terminated or withdrawn. Davidzon, Guido, M.D. leads this study, which shows 8 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2023 — Jul 2024 [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated
Sep 2022 — Dec 2023 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
May 2022 — Sep 2022 [monthly]

Recruiting PHASE2

▶ Show 3 earlier versions

Apr 2021 — May 2022 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Apr 2021 [monthly]

Not Yet Recruiting PHASE2
May 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Davidzon, Guido, M.D.

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States